Shots:
- The 2 P-III (STOP-HS1 & STOP-HS2) trials assessed povorcitinib (45 or 75mg, QD, PO) vs PBO in mod. to sev. HS pts (≥18yrs.; n=600 each) for 12wks., followed by 42wk. extension & 30-day follow-up
- STOP-HS1 met its 1EP, with povorcitinib (45 mg/75 mg) showing higher HiSCR50 rates at Wk. 12 (40.2%/40.6% vs 29.7%), while a biologics-experienced subgroup also showed higher response (34.2%/37.8% vs 21.9%), with >3-pt. Skin Pain NRS reductions (incl. NRS30), fewer flares, & rapid onset
- STOP-HS2 also met its 1EP of superior HiSCR50 rates at Wk. 12 (42.3%/42.3% vs 28.6%), with higher response in mentioned subgroup (45.0%/40.0% vs 19.5%); data to support regulatory filings & presented at future meetings
Ref: Incyte | Image: Incyte
Related News:- Incyte Highlights P-III (TRuE-PN) Clinical Program Data of Opzelura (1.5% Ruxolitinib Cream) for Prurigo Nodularis (PN) at AAD 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
